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Abstract
Gaucher disease (GD), the most common lysosomal storage disorder, results from the inherited deficiency of the lysosomal
enzyme glucocerebrosidase (GCase). Previously, wildtype GCase was used for high throughput screening (HTS) of large
collections of compounds to identify small molecule chaperones that could be developed as new therapies for GD.
However, the compounds identified from HTS usually showed reduced potency later in confirmatory cell-based assays. An
alternate strategy is to perform HTS on mutant enzyme to identify different lead compounds, including those enhancing
mutant enzyme activities. We developed a new screening assay using enzyme extract prepared from the spleen of a patient
with Gaucher disease with genotype N370S/N370S. In tissue extracts, GCase is in a more native physiological environment,
and is present with the native activator saposin C and other potential cofactors. Using this assay, we screened a library of
250,000 compounds and identified novel modulators of mutant GCase including 14 new lead inhibitors and 30 lead
activators. The activities of some of the primary hits were confirmed in subsequent cell-based assays using patient-derived
fibroblasts. These results suggest that primary screening assays using enzyme extracted from tissues is an alternative
approach to identify high quality, physiologically relevant lead compounds for drug development.
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Introduction
High throughput screening (HTS) is widely used for the
identification of small molecule leads that can be developed into
pharmacological agents. Assay miniaturization in a 1536 well
format has made it possible to screen large numbers of compounds
at multiple concentrations in primary screens [1]. However, the
optimal conditions for implementing this strategy must be tailored
individually for each drug target before implementing HTS.
A number of HTS assays have been performed to identify
potential lead compounds for several of the lysosomal storage
disorders (LSDs) [2,3,4,5]. Almost all of these screens utilized
purified recombinant enzyme as the enzyme source, mainly due to
the high specificity of the recombinant enzyme, and the
availability of large amounts of the enzyme, since several lysosomal
enzyme preparations are currently available for enzyme replace-
ment therapy (ERT). In addition, most lysosomal enzymes are
hydrolases, which can be formatted into similar fluorogenic
enzyme assays. These conditions enable comparisons between
the different screens, ensuring the selection of specific active
compounds for a specific enzyme target.
Gaucher disease (GD), the most common LSD, is caused by the
deficiency of the lysosomal enzyme glucocerebrosidase (GCase)
(EC 3.2.1.45) [6]. The disorder is characterized by a broad
spectrum of clinical manifestations, including anemia, thrombo-
cytopenia, massive hepatosplenomegaly, bone disease and in the
neuronopathic forms, brain involvement. Treatment options
include ERT, substrate reduction therapy (SRT) [7,8], and, more
recently, chaperone therapy utilizing iminosugar derivatives [9].
ERT, infused intravenously at regular intervals, successfully treats
many of the systemic manifestations of the disease, and has greatly
improved the quality of life for patients with GD [10]. However,
studies with both ERT and SRT have shown that these therapies
have no impact on neurologic manifestations [11]. Moreover, the
cost, especially for the ERT, is prohibitive.
In a previous HTS using recombinant wildtype (WT) GCase,
we identified several novel classes of inhibitor molecules with
potential chaperone activity, but did not find promising enzyme
activators [5]. The lead molecules identified in the screen were
further optimized by medicinal chemistry efforts to improve the
structure activity relationship (SAR). Some of these compounds
were shown to enhance delivery of the enzyme to the lysosome in
patient fibroblasts. The potencies of these compounds as small
molecule chaperones were generally 100 to 1000-fold weaker than
their enzyme inhibitory activities. This discrepancy may result
from the differences in assay format used to measure the effect of
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2the compounds, as the patient-derived cells were used in the
chaperone assay and the recombinant WT enzyme was used in the
original HTS assay. Thus, screening of the library against a
mutant form of the enzyme might facilitate the identification of
higher quality lead compounds for drug development.
Over 300 mutations in the GCase gene, GBA1, have been
described [12]. Many cause a single amino acid change, resulting
in reduced enzyme activity. The most common mutation in type 1
GD occurs at position c.1226 A.G, causing an N370S amino acid
change [13,14,15]. Patients with this mutation exhibit variability
in phenotype, ranging from asymptomatic individuals to those
with severe visceral involvement or bone disease[16]. Thus, the
N370S mutant form of the enzyme was selected for the current
HTS. In this study we evaluate the use of patient tissue-derived
enzyme for HTS and for the validation of lead compounds
identified from library screens.
Materials and Methods
Reagents and chemicals
Imiglucerase, a recombinant wildtype GCase, was obtained
from Genzyme Corporation (Cambridge, MA). N370S recombi-
nant GCase was a gift from Dr. Tim Edmunds at Genzyme. 4-
methylumbelliferyl-b-D-glucopyranoside (4MU-b-glc), a blue
fluorogenic substrate, resorufin b-D-glucopyranoside (res-b-glc),
a red fluorogenic substrate, sodium taurocholate (NaTC), and
buffer components were purchased from Sigma-Aldrich (St. Louis,
MO). Isofagomine and N- (n-nonyl) deoxynojirimycin (Nonyl-
DNJ) were purchased from Toronto Research Biochemicals
(Ontario, Canada). Conduritol b-epoxide (CBE) was purchased
from Biomol International (Plymouth Meeting, PA). Recombinant
SapC (Swiss protein P20097), expressed in E. Coli according to the
published sequence, was purchased from Genscript (NJ). A mutant
form of the SapC peptide with mutation L349P was generated as
well [17].
The NIH Chemical Genomics Center compound library was
used for the HTS.
Spleen tissue preparation
Patient and control spleen samples were obtained from tissue
collected at splenectomy or autopsy with written informed consent.
The study was approved by the National Human Genome
Research Institute Review Board, under permit code: National
Insts Hlth - NHGRI - IRB #14. Enzyme extracts from spleen
were evaluated as a native source of mutant enzyme for the GCase
assay for use in large-scale compound screening. GCase activity
was assayed in extracts from spleens from several patients with GD
with genotype N370S/N370S. The sample with the highest
activity, N370S/N370S-1, was selected as the mutant enzyme
preparation for both the HTS and further experiments (Figure S1).
Ninety grams of minced tissue was placed in 600 ml of ice-cold
extraction buffer (50 mM Citrate 175 mM KH2PO4 0.01%
Tween-20 pH 5.9). The tissue was then homogenized using a
food blender at maximum speed for 5 minutes, followed by 10
passes in a motor-driven 50 ml glass-Teflon homogenizer (setting
10; nominal clearance, 0.13–0.18 mm). The homogenate was
centrifuged at 10006g for 10 min. The supernatant was passed
through a 40 mm filter and aliquots of the resultant spleen
homogenate were frozen at 280uC until use.
Buffers for enzyme assay with spleen extract
The assay buffer consisted of 50 mM citric acid, 115 mM
K2HPO4, 110 mM KCl, 10 mM NaCl, 1 mM MgCl2, and 0.01%
Tween-20 at pH 5. A solution of 1 M NaOH and 1 M glycine at
pH 10.0 was used as the stop solution to increase the fluorescence
signal.
HTS validation in 1536-well plates
In a black 1536-well plate (Greiner Bio-one, Monroe, NC),
2 ml/well of spleen homogenate containing 27 mg protein were
incubated with 23 nl of DMSO solution for 5 minutes, followed by
the addition of 2 ml/well 4MU-b-glc to a final concentration of
1 mM. After a 30-minute incubation at 37uC, the enzyme reaction
was terminated with the addition of 2 ml/well of the stop solution.
The fluorescence was then measured in a CCD-based plate
reader, ViewLux (Perkin Elmer, Waltham, MA) with an excitation
at 365 nm and emission at 440 nm. A BioRAPTR FRD
TM
Microfluidic Workstation (Beckman Coulter, Inc. Fullerton, CA)
was used to dispense reagents into 1536-well plates, and an
automated pin-tool station (Kalypsys, San Diego, CA) was used to
transfer 23 nl/well of compound to the assay plate. Nonyl-DNJ, a
known GCase inhibitor, was used as a control compound in this
assay.
The initial assay, tested in the 1536-well plate format with the
solvent DMSO, showed a signal-to-basal ratio of 20-fold, a CV of
6.3% and a Z9 factor of 0.91. Subsequently, all compounds were
screened at seven concentrations (1:5 serial dilutions) [1,18]. The
active compounds from the qHTS were selected based on their
EC50/IC50 values and concentration response curves.
Validation of the ability of selected compounds to
chaperone in a cell based assay
Patient fibroblasts were seeded in 96 well glass bottom plates
(Greiner Monroe, NC). After 48 hours they were treated with five
compounds identified from the screening assay using N370S/
N370S spleen homogenate and NCGC00092410, which was
identified from the recombinant WT screen. In addition, cells
were treated with isofagomine and Nonyl-DNJ as positive controls
and DMSO as a negative control. The cells were treated with six
different concentrations of drug (from 1 nm to 50 mM) for five
days, with one replacement of media. Some compounds were
found to be toxic at the highest concentration. Cells were fixed
with 3% paraformaldehyde and stained with a nuclear marker
(Hoechst Invitrogen, Carlsbad, CA), the lysosomal marker
LAMP2 (H4B4 Abcam, Cambridge, MA), and anti-GCase (in
house antibody Rabbit 386). Regions of interest (ROI) were
determined by LAMP2 localization in 4 fields/well, and the
intensity of GCase staining was measured in the ROI using an
Figure 1. pH profiles of recombinant N370S and WT GCase. The
assay was performed in the presence of 10 mM NaTC. While the WT
enzyme has a pH optimum of 5.9, the N370S enzyme has a broad
optimum of around pH 7.2.
doi:10.1371/journal.pone.0029861.g001
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for each compound and for each cell culture tested.
Results
Recombinant N370S GCase has a higher pH optimum
and a lower Vmax than wildtype GCase
The activity of the recombinant N370S mutant enzyme was first
compared to WT enzyme. We found that the pH optimum of the
mutant enzyme was 7.2, versus 5.9 for the WT enzyme (Fig. 1).
The N370S enzyme also had a reduced Vmax toward two
different fluorogenic (red and blue) substrates when assayed in the
presence of NaTC at pH 5.9, the optimal pH for WT enzyme.
The Vmax values were 11.7 pmole/min and 41.9 pmole/min and
the Km values were 33.3 mM and 31.3 mM for the mutant and
WT enzyme, respectively. The mutant enzyme activity was 27.9%
of the WT enzyme as calculated by the Vmax values. However, the
activity of the mutant enzyme was significantly lower at acidic pH,
and was virtually absent at pH 5, the normal lysosomal pH.
The activities of three inhibitors identified in the previous HTS
[19] were tested with recombinant WT and N370S GCase, as well
as spleen tissue extracts from controls and patients with genotype
N370S/N370S. In the recombinant N370S enzyme assay, all
three GCase inhibitors exhibited a 24- to 31-fold reduction in
activity, as compared with the recombinant WT enzyme assay
(Fig. 2). The inhibitory activities were further reduced (.700-fold)
for two of the inhibitors, NCGC00092410 and NCGC00060210
in the assays using WT and N370S spleen extracts. The results
demonstrated that the inhibitors exhibited very different activities
with the different enzyme preparations tested.
WT and mutant spleen GCase have a lower and identical
pH optimum, and are less dependent on NaTC
The pH optimum of endogenous GCase in the WT spleen
extract was below 5 (Fig. 3a). A similar profile was obtained for the
N370S spleen (Fig. 4c). The enzyme activity of both the WT and
mutant spleen extract had a lower dependence on NaTC than WT
recombinant enzyme, with about 2-fold activation compared to
more than 20-fold respectively (Figs. 3b, 4a). In order to
discriminate between GCase and other glycosidase enzymes
capable of cleaving the substrate, spleen preparations were treated
with the GCase-specific inhibitor conduritol b-epoxide (CBE) [20].
In both WT and N370S spleen extracts, the amount of activity not
inhibited by CBE at pH 5 was minimal, indicating that the other
glucose hydrolases do not play a major role in this assay using the
rough enzyme preparation (Fig. 3c).
The Vmax of the endogenous mutant GCase from N370S spleen
was lower than that from WT spleen, with values of 9.3 and
22.6 pmol/mg protein/min respectively, while the Km was
similar, 1917 mM for N370S and 1519 mM for WT spleen
enzyme. Thus, the deficient GCase activity in lysosomes in
N370S/N370S patients may result from both the reduced amount
of mutant protein delivered to the lysosome, and the decreased
catalytic ability of the mutant enzyme.
Recombinant WT GCase adopts the characteristics of
spleen enzyme when it is spiked into the spleen
preparation
The lower pH optimum of spleen-derived GCase compared to
recombinant enzyme, and its lack of activity-dependence on
Figure 3. Characterization of spleen GCase activity. A. pH optimum, B. NaTC dependency, C. Inhibition of spleen GCase activity by CBE.
doi:10.1371/journal.pone.0029861.g003
Figure 2. Concentration responses of three GCase inhibitors determined using recombinant WT GCase, recombinant N370S mutant
enzyme, WT GCase from normal spleen extract and N370S mutant enzyme from a spleen of a patient with GD (genotype N370S/
N370S). The three inhibitors were identified from the previous HTS using recombinant WT GCase.
doi:10.1371/journal.pone.0029861.g002
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on the recombinant enzyme activity were assayed. A. activity of WT recombinant enzyme with and without NaTC. B and C. Different dilutions of
N370S spleen in the presence (B) or absence (C) of NaTC. D. and E. WT recombinant enzyme mixed with increasing concentrations of spleen extract
with (D) and without (E) NaTC.
doi:10.1371/journal.pone.0029861.g004
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components critical for optimal enzyme activity. To further
demonstrate this hypothesis, we added WT recombinant enzyme
to N370S spleen extract with and without NaTC before the
measurement of the GC activity. Without NaTC, the activity of
the recombinant WT enzyme was only 5% of that seen in the
presence of NaTC but its pH optimum shifted to ,5 (Fig. 4a). The
GCase activity in the N370S spleen extract remained the same in
the presence or absence of NaTC. (Figs. 4b,c). The pH optimum
was also lower without NaTC. Moreover, the GCase activity of
the N370S spleen preparation increased further when the
concentration of spleen extract increased from 1/32 to 1/8
without NaTC (7-fold), compared with NaTC (2.5-fold), at
optimal pH (Figs. 4b,c). In the final step of this experiment,
recombinant WT enzyme, which was dependent on NaTC
(Fig. 4a), was added to the N370S spleen extract and the activity
determined. Figures 4d,e show the activity of WT GCase after
subtracting the contribution of endogenous N370S GCase
(Figs. 4b,c). In the presence of N370S spleen extract without
NaTC, the pH optimum of recombinant WT enzyme was also
lowered from 5.9 to 5, and the activity was dependent on the
concentration of the spleen extract (Fig. 4e). In contrast, in the
presence of NaTC, the activity was not dependent on the
concentration of spleen extract (Figs. 4d,e). Similar results were
obtained using the recombinant N370S enzyme, where the pH
optimum was reduced from neutral to approximately 5. Thus,
while the parameters of recombinant GCase activity measured in
the presence of the spleen extract resembled those of the spleen
homogenate, the spleen component involved in activating the
enzyme was obscured by the NaTC.
SapC and PS are the critical components found in GCase
preparations from spleen
The difference in the activity profile of recombinant enzyme in
the presence of spleen homogenate, compared to the same enzyme
in assay buffer, raised the possibility that other factors in the spleen
homogenate compensated for the enzyme activation property of
NaTC. We explored the role of SapC, a natural cofactor of
GCase. SapC was previously shown to compete with NaTC in
activating GCase [21].
The enzyme activities of recombinant WT (5 nM) and N370S
GCase (100 nM) were tested in the presence of SapC and
phosphatidyl-serine as described [22]. We found that the enzyme
activity was eight-fold higher in the presence of SapC than the
basal level. The maximal enzyme activity in the presence of SapC
was higher than that obtained in the presence of 10 mM NaTC
(Fig. 5). While both enzymes showed activity at a wide pH range in
the presence of NaTC, their peak activity in the presence of SapC
was narrowed to around pH 5 with very little activity at neutral
pH. The effect of mutant SapC on activation of these enzymes was
limited (data not shown). The results indicated that in the presence
of SapC and phosphatidyl-serine, the pH optimum and enzyme
activity of both recombinant GCases were similar to those of the
spleen homogenate.
A compound screen using GCase from the spleen
preparation yields both activators and inhibitors of
GCase
A library of 250,000 compounds was screened at five distinct
compound concentrations using mutant N370S GCase from
Figure 5. Effect of SapC versus NaTC on the activity of WT (A) and N370S recombinant (B) GCase. In the presence of SapC, the activity of
both WT (A), N370S (B) enzyme gave a sharp peak near pH 5, compared to the broader peak and higher pH seen using NaTC.
doi:10.1371/journal.pone.0029861.g005
Table 1. Classification of active compounds identified from the screen assay using the N370S mutant enzyme in spleen tissue.
Activity Distribution Curve Classification*
1.1 1.2 1.3 1.4 2.1 2.2 2.3 2.4 3 4 5
Activation # of compounds 30 212 0 95 526 2116 0 421 1135 237353 519
% of library 0.01% 0.09% 0.00% 0.04% 0.21% 0.86% 0.00% 0.17% 0.46%
Inhibition # of compounds 14 75 0 344 22 1175 0 242 1394 96.61% 0.21%
% of library 0.01% 0.03% 0.00% 0.14% 0.01% 0.48% 0.00% 0.10% 0.57%
*Criteria for classification of compounds are described in table S2.
doi:10.1371/journal.pone.0029861.t001
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results of this screen were deposited in PubChem (AID 2101)
[23]. In order to eliminate the false positive compounds, the
primary screen results were first compared to those from two
other previous screens for alpha-glucosidase and alpha-galacto-
sidase using similar fluorogenic substrates [2,3]. Ultimately, a set
of 30 lead GCase enzyme activators and 14 potent enzyme
inhibitors were identified as primary active compounds meriting
further validation (Table 1). Five of these compounds were
selected for further validation as a proof-of principle and are
described in Table 2.
Cell based assays confirm the chaperone activity of
GCase activators and inhibitors
Fibroblasts from patients with GD having the following
genotypes: N370S/N370S (severe visceral phenotype), N370S/
N370S (mild phenotype), L444P/L444P, and L444P/RecNci1,
were incubated for 5 days with the selected active compounds
identified in the primary screen, as well as compounds known to
have GCase chaperone activity. The intensity of GCase staining in
lysosomes was determined using automatic fluorescence micros-
copy. The slope of the dose dependent increase in fluorescence
above the DMSO baseline was calculated using linear regression
(Figure 6), and slopes with statistical significance (P,0.05)
are indicated. Some compounds, including the activator
NCGC00182186, were able to increase the lysosomal content of
both N370S and L444P mutant enzymes. In a parallel experiment,
the effect of these compounds on GCase activity was tested in the
same cells (Table 2). In addition, compounds were tested for
binding properties as well as their effect on the thermal stability of
the recombinant enzyme (not shown). Several of the active
compounds discovered in the qHTS were chosen for SAR studies
and optimized compounds continue to be subjected to further
preclinical studies [24].
Table 2. Compounds discovered in the spleen qHTS tested
for modulation of GCase activity and GCase translocation in
cell assays.
Compound Series Effect Potency
Enzyme
assay* Translocation**
(micromolar)
MLS000674724 Hydroxidiasole Inhibitor 0.4 22
NCGC00182292 Quinazoline Inhibitor 0.25 +2
NCGC00159568 Thiourea Inhibitor 0.31 ++
NCGC00182186 Carboxyamide Activator 3 ++
NCGC00182510 Benzoate Inhibitor 1 +2
*As measured on spleen enzyme preparation.
**Translocation experiments performed on WT, N370S/N370S, L444P/L444P and
L444P/RecNci1 fibroblasts.
doi:10.1371/journal.pone.0029861.t002
Figure 6. Dose response increase in lysosomal content of GCase in fibroblasts treated with selected identified compounds. Cells
were treated with six drug concentrations (1 nM to 50 mM) for 5 days. The intensity of GCase staining in the lysosomes was measured using an
automatic fluorescent microscope. The slope of dose dependent increase in fluorescence was plotted and statistically significant slopes are labeled
with (*). Some compounds, including the activator NCGC00182510, were able to increase the lysosomal content of both N370S and L444P mutant
enzymes. Some compounds were found to be toxic at the highest concentration and that point was removed from calculations.
doi:10.1371/journal.pone.0029861.g006
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and fewer inhibitors than identified using recombinant
GCase
To compare the results of primary screens using the N370S
spleen enzyme with those from recombinant WT GCase, we
analyzed the 52,000 compounds that were screened using both
enzyme preparations. The primary screen with GCase from
N370S spleen tissue yielded a relatively smaller number of active
molecules, and only about 8% of the total number of hits found in
the screen using the recombinant WT enzyme were identified in
the current screen (Fig. 7a). Approximately 92% of potent
inhibitors identified in the initial screen with the recombinant
WT enzyme were not detected in the current screen using the
spleen enzyme extract (Fig. 7b, Table S1). In addition, about 97%
of robust activators identified in the current screen using enzyme
extract from N370S spleen, were not detected in the previous
screen using recombinant WT enzyme. Most of the newly
identified hits in the screen with N370S mutant enzyme were
activators of the mutant enzyme. A few compounds that showed
activator properties in the current screen but were identified as
‘‘inhibitors’’ in the previous screen using the WT recombinant
enzyme were eliminated based on their fluorescence and non-
selective properties.
The difference in the results of the two screens is
attributed to the presence of Sap C and PS in the spleen
preparation
We then selected a set of compounds and evaluated their
activities in the presence of SapC or NaTC using the different
enzyme preparations (Fig. 8). Some of the compounds exhibited
relatively high inhibition of GCase activity with the recombinant
enzyme in the presence of NaTC, but much weaker inhibition in
the assay using enzyme extract from spleen tissue (Fig. 8a). Their
inhibitory activities to the recombinant enzyme were reduced
significantly when SapC replaced NaTC in the enzyme assay
(Fig. 8b). On the other hand, some of the activator compounds
that were more active with the N370S enzyme extract from
spleen showed much weaker or no activity with the recombinant
enzyme in the presence of NaTC (Fig. 8c). These compounds
became more active in the same recombinant enzyme assay
when NaTC was replaced with SapC (Fig. 8d). These results
indicate that the activities of some of the compounds in the GC
assay with the WT recombinant enzyme were likely dependent
on NaTC, which may explain the reduced activity in the cell-
based assays.
Discussion
The use of recombinant WT proteins for high throughput
screening is widely employed, and often leads to the identification
of novel enzyme inhibitors. However, in the case of lead
compound discovery for GCase, we sought to explain the weaker
activities in cell-based assays testing lead compounds previously
identified in screens using recombinant WT enzyme. We
hypothesized that native cofactors of GCase absent from the
recombinant enzyme preparation might be responsible for the
discrepancy in the activities of these inhibitors, and that this might
be corrected by an alternative screening strategy using enzyme
extracted from patient tissues. In addition, the screen with
recombinant WT GCase did not yield candidate enzyme
activators, suggesting that screens using WT enzyme might not
be appropriate for the detection of activators.
We found that some previously identified inhibitors had reduced
potency when tested in the assay using enzyme extracts from WT
and patient tissues. This suggested that GCase screening using
patient tissue extracts could identify a different set of active
compounds from the primary screen.
The initial HTS assay was adopted from the clinical diagnostic
procedure for determining GCase activity in patient samples. This
assay requires NaTC in the buffer to activate the enzyme. While
this assay format is useful for the diagnosis of GD, it has limitations
when used for compound screens. First, this assay is performed at
pH 5.9, which is the optimal pH for the enzyme reaction in the
presence of NaTC. However, the lysosome usually has a pH of 4.5
to 5. Thus, the enzyme may have different conformations in these
different pH environments, resulting in different sensitivities to
small molecules. Second, essential native co-factors of GCase,
including SapC and phosphatidyl-serine, are missing in the
purified recombinant enzyme mix, and their absence may also
change the enzyme conformation significantly. Third, a combi-
nation of recombinant WT enzyme and high concentrations of
NaTC serve to optimize the enzyme assay to a high activity level,
which may prevent the identification of activators from the
Figure 7. Comparison of the active compounds identified in
the WT and N370S HTS experiments. A. Distribution of active
compounds in the WT (blue) and N370S/N370S spleen (red) HTS
experiments. B. Overlap between active compounds tested in both
experiments by type of activity.
doi:10.1371/journal.pone.0029861.g007
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because it is the actual drug target.
Our studies show that enzyme extracts from WT and patient
tissues had a pH optimum of 5, closer to the lysosomal pH (Fig. 3).
We then found that when the recombinant enzyme was tested in
the presence of a small amount of spleen homogenate, it acquired
the characteristics similar to the enzyme extract from spleen,
including a reduced dependence on NaTC and a lower pH
optimum (Fig. 4). These results indicated that enzyme extract from
spleen contains native cofactors absent from the recombinant
enzyme. Stimulating the activity of the recombinant enzyme with
NaTC shifts the pH optimum to 5.9, which is above lysosomal pH.
We found that recombinant WT enzyme acquired character-
istics similar to the native enzyme when the NaTC in the buffer
was replaced by phosphatidyl-serine and SapC (Fig. 5), suggesting
that the higher pH optimum in the previous assay was due to the
addition of NaTC. With recombinant N370S enzyme, the pH
optimum shifted from 7 in the presence of NaTC to 5 when
phosphatidyl-serine and SapC replaced NaTC. An increased pH
optimum was also noted in cultured fibroblasts from patients with
genotype N370S/N370S in the presence of NaTC [25]. Thus,
the inclusion of NaTC in the buffer may impact the effect of
compounds on enzymatic activity, and subsequently the nature of
compounds identified from library screens. For example, a
compound that interacts with the head-group of taurocholate
may inhibit the enzymatic activity by reducing the enzyme
activation by NaTC. The active conformation of GCase in the
presence of NaTC may be significantly different from the enzyme
in the presence of the physiological cofactors phosphatidyl-serine
and SapC. The enzyme inhibitors could have different affinities
to these two different active conformations of GCase (i.e. in the
presence of native co-factors or in the presence of NaTC). These
may have contributed to the discrepancy in inhibitory activities
found between the assay with recombinant enzyme in the
presence of NaTC and that using enzyme extract from spleen
tissue (Fig. 7).
The N370S mutant enzyme was selected for compound
screening because it is among the most common Gaucher
mutations. Moreover, since the Vmax value of the N370S mutant
form of the enzyme is reduced, it can facilitate the detection of
small molecule compounds that can increase activity of this
mutant enzyme. Thus, the compound library screens can target
small molecules that increase the Vmax of N370S mutant enzyme
and thus enhance enzyme activity in late endosomes and
lysosomes [26].
The use of recombinant mutant enzyme for HTS might seem
advantageous because the target protein is pure and the enzyme
specificity is high. However, the activation of a non-native enzyme
confirmation by NaTC could lead to another set of false positive
compounds that may be less active later in confirmatory cell-based
assays. Thus, for the current screen of 250,000 compounds, we
used the enzyme extract from spleen of a patient with GD
(genotype N370S/N370S). Frozen tissue samples from patients
with GD harboring mutations such as N370S are readily available
because, in the past, many patients underwent splenectomies to
reduce their disease burden. The significant residual activity of
GCase associated with this mutant form of the enzyme was an
asset in the screen assay development. While nonspecific
compounds were also found in the screen due to the use of this
rough preparation, they were readily eliminated later in the
secondary and tertiary screens with cell-based assays (Fig. 6).
Structurally, the WT and N370S forms of GCase are quite
similar [27], and hence, one might expect similar results from
compound library screens for the two enzymes. However, because
Figure 8. Potency of selected compounds in the WT and N370S mutant enzyme assay with NaTC or SapC. Compound NCGC0092410
(NCGC), discovered in the recombinant WT HTS, inhibited the WT enzyme much better than N370S in NaTC (A), but showed less inhibition of WT
enzyme in the SapC assay (B). Compound MLS000393962 (MLS) (C,D), identified in the N370S/N370S spleen HTS, inhibited the WT recombinant
enzyme, and had no effect on the recombinant N370S enzyme with the addition of NaTC (C). However, in the presence of SapC (D), there was an
enhanced inhibitory effect on the WT enzyme as well as the N370S enzyme. * No trendline fit possible.
doi:10.1371/journal.pone.0029861.g008
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from the N370S spleen yielded a new set of active compounds not
found using recombinant WT enzyme. Moreover, certain active
compounds previously found in the screen using recombinant WT
enzyme had far lower activities in the assay using enzyme extract
from spleen, suggesting that NaTC might interact with these
compounds or alter the enzyme’s confirmation (Fig. 8). Thus, the
use of enzyme extract from patient tissue in the primary screen
may identify new lead compounds not identified in screens using
recombinant enzymes.
The screen with mutant enzyme also improved our ability to
discover enzyme activators, especially those enhancing the activity
of mutant enzyme. Compounds with activation properties were
found at a 3.6-fold higher rate in the current screen than that in
the previous screen using recombinant WT enzyme. Selective
activators of the enzyme are usually allosteric binders. These
enzyme activators with chaperone activity should better assist the
movement of mutant proteins from the ER to the lysosome,
because they do not need to be released from the enzyme in the
lysosome to hydrolyze the substrate. This mechanism of action
differs from enzyme inhibitor-based chaperones, where the
inhibitors must be released from the mutant proteins in the
lysosome before the enzyme can be functional. Thus, the dosing of
activator-based chaperone therapy is much simpler, facilitating
preclinical and clinical development.
The results observed when SapC replaced NaTC in the assay
using recombinant enzyme indicate that both the WT and mutant
forms of the enzyme have a similar affinity to the compounds
discovered in the HTS using enzyme extract from spleen. This
suggests that the difference between the two enzymes is primarily
the decreased Vmax value in the N370S mutant enzyme. Thus,
activators that can increase the Vmax value of N370S enzyme
might be useful for the treatment of other mutant forms of GCase.
It has been reported that with deoxynojirimycin, an inhibitor-
based iminosugar chaperone compound developed for the
treatment of Pompe disease, only a fraction of mutant forms of
a-glucosidase responded to the treatment [28]. In contrast,
activators bind in a location distant from the active site, and
therefore may be useful for a wide range of mutations.
In conclusion, this study is the first utilizing enzyme extract from
patient tissue for HTS of compound libraries to identify enzyme
activators and inhibitors. Several of the lead compounds identified
are currently being developed and tested as possible therapies for
patients with Gaucher disease. This new screening strategy can
also be applied to lead discoveries for other diseases where frozen
tissue specimen may be readily available. The use of enzyme
extracts from patient tissues has several advantages for HTS
including relatively easier enzyme preparation (especially for
mutant enzymes), a physiologically relevant enzyme environment
for better lead discovery, and a much simplified screen assay over
the cell-based assays. In addition, it is likely that more activators
will be found using the enzyme extracts derived from patient
tissues and the compound activities in this assay will correlate
better later with those in cell-based confirmatory assays.
Therefore, adaptation of this new screening strategy may greatly
facilitate lead discovery as well as the ‘‘hit to lead’’ progression in
the early drug discovery process.
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recombinant enzyme screen (columns) and in the N370S spleen
screen (rows) are presented by type of activity. The numbers of
compounds active in only one screen are presented in the last
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